Welcome to LookChem.com Sign In|Join Free

CAS

  • or
C33H44N6O6S is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1225450-99-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1225450-99-6 Structure
  • Basic information

    1. Product Name: C33H44N6O6S
    2. Synonyms: C33H44N6O6S
    3. CAS NO:1225450-99-6
    4. Molecular Formula:
    5. Molecular Weight: 652.815
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1225450-99-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C33H44N6O6S(CAS DataBase Reference)
    10. NIST Chemistry Reference: C33H44N6O6S(1225450-99-6)
    11. EPA Substance Registry System: C33H44N6O6S(1225450-99-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1225450-99-6(Hazardous Substances Data)

1225450-99-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1225450-99-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,5,4,5 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1225450-99:
(9*1)+(8*2)+(7*2)+(6*5)+(5*4)+(4*5)+(3*0)+(2*9)+(1*9)=136
136 % 10 = 6
So 1225450-99-6 is a valid CAS Registry Number.

1225450-99-6Upstream product

1225450-99-6Downstream Products

1225450-99-6Relevant articles and documents

Antiangiogenic effect of dual/selective α5 β1/αvβ3 integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics

Gentilucci, Luca,Cardillo, Giuliana,Spampinato, Santi,Tolomelli, Alessandra,Squassabia, Federico,De Marco, Rossella,Bedini, Andrea,Baiula, Monica,Belvisi, Laura,Civera, Monica

experimental part, p. 106 - 118 (2010/04/24)

Recent evidence highlighted the role of α5β 1 integrin in angiogenesis and in regulating α vβ3 integrin function. As a consequence, selective α5β1 integrin inhibitors or dual α5β1/αvβ3 integrin inhibitors are considered promising candidates for the development of cancer therapeutic agents. In this paper, we describe the synthesis and pharmacological characterization of a minilibrary of cyclotetrapeptide mimetics containing a PMRI Arg-Gly-Asp sequence. In particular, c[(R)- βPheψ(NHCO)Aspψ-(NHCO)Gly-Arg] (3) displayed a good activity in inhibiting the αvβ3 integrin-mediated cell adhesion of fibronectin or vitronectin, as well as the adhesion of fibronectin to the α5β1 integrin. Interestingly, the diastereomeric compound c[(S)-βPheψ(NHCO)Aspψ(NHCO)Gly-Arg] (2) maintained a good efficacy in inhibiting α5β1 integrin while gaining a certain selectivity over αvβ 3 integrin. These two integrin antagonists significantly inhibited bFGF-induced human endothelial cell tube formation at submicromolar concentrations. Conformational analysis and Molecular Docking calculations suggest that the different α5β1 versus αvβ3 selectivity of 2 and 3 can be rationalized on the basis of the alternative display of the aromatic side chain adjacent to Asp.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1225450-99-6